

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Market Research Report | 2023-04-21 | 135 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This study provides a comprehensive analysis of CNS biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the global CNS biomarkers market.

Current and projected product forecasts during the forecast period (2022 to 2027) are discussed. New products approved in 2021 and 2022 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Market figures for 2022 are estimated, except where actual results have been reported.

Included in this report are forecasts by biomarker type, technology type, disease, application, and region from 2022 through 2027. The report also includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care.

Report Includes:

- 43 tables
- An overview of the global market and technologies for central nervous system (CNS) biomarkers
- Estimation of the market size and analyses of market trends, with data from 2019 to 2021, estimates for 2022, and projections

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

of compound annual growth rates (CAGRs) through 2027

- Explanation of market drivers, restraints and other forces impacting the global market
- Description of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer's disease, depression, Parkinson's disease, multiple sclerosis, and others
- Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Abbott, Bio-Rad Laboratories Inc., Eisai Co. Ltd., Merck and Thermo Fisher Scientific Inc.

Executive Summary

Summary:

Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, indicate what treatment options may be most effective in an individual patient's case, and predict treatment response. They play a role both in new drug R&D and in predicting the outcome of treatment in the medical setting. Biomarkers are important tools for understanding disease mechanisms, developing more effective treatments and improving the quality of patient care.

A biomarker of a central nervous system (CNS) disorder is, by definition, differentially expressed between a normal subject's brain or spinal cord (CNS system) and that of a subject bearing a CNS disorder. Traditionally, CNS or neuroscience biomarkers could only be detected after a subject already exhibited cognitive decline or other symptoms of disease. However, recently, sensitive assays have shown biomarkers to be present even in advance of other symptoms.

The global CNS biomarker market was valued at \$REDACTED billion in 2022. The market is projected to reach \$REDACTED billion in 2027, growing at a CAGR of REDACTED% during the forecast period. This aggressive growth rate will be driven by several factors, including the increase in public-private partnerships with government support, pressure to keep healthcare costs down, a growing elderly population, and the rapid advancement of the genomic and proteomic technologies that have impacted the CNS biomarker diagnostics area.

There is huge unmet need in the area of CNS diseases due to the lack of fast and sensitive diagnostic methods and effective treatments. CNS biomarkers are rapidly emerging as the mainstay in the identification of patients at risk, early diagnosis, follow-up of disease progression, and effectiveness of treatments in neurology, in particular for demyelinating diseases (such as multiple sclerosis), neurodegenerative diseases (such as Alzheimer's disease) or traumatic brain injury.

In order to expedite drug development for neurology diseases, it is important to identify novel biomarkers that enhance diagnostic and prognostic accuracy, improve the existing decision criteria for early diagnosis and risk stratification, assist in disease monitoring, and act as surrogate endpoints in experimental studies and clinical trials. Efforts are being directed to expand neurology research and develop platforms and methods that can provide deeper insights into brain biology and aid in further biomarker research. Several biomarkers that have been identified in the past decade are under investigation for their potential applications. Once these biomarkers are validated and subsequently enter into clinical and research applications, the CNS biomarkers marker is expected to grow significantly.

Table of Contents:

Table of Contents

Chapter 1 Introduction

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 What's New in This Update?
- 1.4 Scope of Report
- 1.5 Methodology and Information Sources
- 1.6 Geographic Breakdown
- 1.7 Analyst's Credentials
- 1.8 BCC Custom Research
- 1.9 Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Market and Technology Background
 - 3.1 Overview of Biomarkers
 - 3.2 Classification of Biomarkers
 - 3.3 Types of Biomarkers
 - 3.4 Biomarker Discovery, Verification and Validation
 - 3.4.1 Surrogate Biomarkers/Endpoints
 - 3.5 Overview of Central Nervous System (CNS)
- Chapter 4 Market Dynamics
 - 4.1 Drivers
 - 4.1.1 Growing Incidence and Financial Burden of Neurological Disorders
 - 4.1.2 High Unmet Need in Neurodegenerative Disorders
 - 4.1.3 Need to Reduce Drug Development Costs and Failures
 - 4.1.4 Increasing investment in Neuroscience
 - 4.1.5 Developments in Analytical Technologies and Assay Methods
 - 4.1.6 Support from Regulatory Agencies
 - 4.2 Restraints
 - 4.2.1 Technological Challenges
 - 4.2.2 Regulatory and Reimbursement Challenges
- Chapter 5 Market Breakdown by Disease
 - 5.1 Market Overview
 - 5.2 Alzheimer's Disease (AD)
 - 5.2.1 AD Pathophysiology
 - 5.2.2 Prevalence and Incidence
 - 5.3 Key Biomarkers of AD
 - 5.3.1 Amyloid-beta (AB, Beta Amyloid, or Abeta)
 - 5.3.2 Tau Protein
 - 5.3.3 Other Biomarkers of AD
 - 5.3.4 Emerging Need for Blood-Based AD Biomarkers Testing
 - 5.4 Parkinson's Disease (PD)
 - 5.4.1 Prevalence and Incidence
 - 5.5 Key Biomarkers of PD
 - 5.5.1 DaTscan (Ioflupane I 123 Injection)
 - 5.5.2 Flouro-dopa F18 (F-Dopa)
 - 5.5.3 Alpha synuclein (a-synuclein)
 - 5.5.4 Other Biomarkers of PD
 - 5.6 Multiple Sclerosis (MS)
 - 5.7 Key Biomarkers of MS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.7.1 Neurofilament Light (NfL)
- 5.7.2 Myelin Basic Protein (MBP)
- 5.8 Amyotrophic Lateral Sclerosis (ALS)
- 5.9 Frontotemporal Dementia (FTD)
- 5.10 Key Biomarkers of ALS and FTD
 - 5.10.1 TAR DNA-Binding Protein 43 (TDP-43)
 - 5.10.2 Neurofilament Light Chain (NfL)
- 5.11 Traumatic Brain Injury (TBI) or Concussion
- 5.12 Traumatic Spinal Cord Injury (SCI)
- 5.13 Key Biomarkers/Hallmarks of TBI or SCI
 - 5.13.1 Glial Fibrillary Acidic Protein (GFAP)
 - 5.13.2 Ubiquitin C-terminal Hydrolase (UCH-L1)
 - 5.13.3 Neurofilament-Heavy (NF-H) and Light (NF-L)
 - 5.13.4 S100 Calcium-binding Protein B (S100B)
- 5.14 Other Diseases
 - 5.14.1 Rare Brain Diseases
- 5.15 Global Market for CNS Biomarkers by Disease
 - 5.15.1 Alzheimer's Disease (AD)
 - 5.15.2 Parkinson's Disease (PD)
 - 5.15.3 Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD)
 - 5.15.4 Traumatic Brain and Spinal Cord Injuries
 - 5.15.5 Others
- Chapter 6 Market Breakdown by Application
 - 6.1 Market Overview
 - 6.2 Life Science Research
 - 6.3 Drug Discovery and Development
 - 6.4 Clinical Diagnostics
 - 6.5 Personalized Medicine
 - 6.5.1 Precision Health Screening/Disease Risk Assessment
 - 6.6 Global Market for CNS Biomarkers, by Application
 - 6.6.1 Life Science Research
 - 6.6.2 Drug Discovery and Development
 - 6.6.3 Clinical Diagnostics
 - 6.6.4 Personalized Medicine
- Chapter 7 Market Breakdown by Technology Type
 - 7.1 Market Overview
 - 7.2 Proteomics
 - 7.2.1 Proteomics Technologies
 - 7.3 Imaging
 - 7.4 Genomics
 - 7.5 Global Market for CNS Biomarkers, by Technology Type
 - 7.5.1 Proteomics
 - 7.5.2 Imaging
 - 7.5.3 Genomics
- Chapter 8 Market Breakdown by Biomarker Type
 - 8.1 Key Biomarkers of Neurodegeneration
 - 8.1.1 Amyloid beta (AB, beta amyloid, or Abeta)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1.2 Tau Proteins
- 8.1.3 Alpha synuclein (a-synuclein)
- 8.1.4 Synapses
- 8.1.5 P53 protein
- 8.1.6 Apolipoprotein E (APOE)-4
- 8.2 Key Biomarkers of Traumatic Brain and Spinal Injuries
 - 8.2.1 Glial Fibrillary Acidic Protein (GFAP)
 - 8.2.2 Ubiquitin C-terminal hydrolase (UCH-L1)
 - 8.2.3 S100 Calcium-binding Protein B (S100B)
 - 8.2.4 Neurofilament-Heavy (NF-H) and Light (NF-L)
- 8.3 Key Biomarker Targets for Neuroinflammation
 - 8.3.1 Brain-derived Neurotrophic Factor (BDNF)
 - 8.3.2 Nerve Growth Factor (NGF)
 - 8.3.3 Proinflammatory Cytokines
 - 8.3.4 Global CNS Biomarkers Market by Biomarker Type
- Chapter 9 Market Breakdown by Region
 - 9.1 Global Market for CNS Biomarkers by Region
 - 9.2 North America
 - 9.3 Europe
 - 9.4 Asia-Pacific
 - 9.5 Rest of the World (RoW)
- Chapter 10 Impact of COVID-19
 - 10.1 Overview
 - 10.2 Impact on CNS Biomarkers Market
- Chapter 11 Competitive Landscape
 - 11.1 Overview
 - 11.2 Product Launches/Approvals
 - 11.3 Collaborations/Partnerships
 - 11.4 SWOT Analysis for Global CNS Biomarker Industry
- Chapter 12 Emerging Products/Technologies in the Market
 - 12.1 Blood Tests for CNS Biomarkers
 - 12.2 Focus on Tau Protein
 - 12.3 Digital Biomarkers
 - 12.4 Emerging Clinically Relevant CNS Biomarker Candidates
- Chapter 13 Company Profiles
 - ABBOTT LABORATORIES LTD.
 - BIOMERIEUX S.A.
 - BIO-RAD LABORATORIES INC.
 - C?N DIAGNOSTICS, LLC
 - DIADEM SPA
 - EISAI CO. LTD.
 - ELI LILLY AND CO.
 - F. HOFFMANN-LA ROCHE AG
 - H.U. GROUP HOLDINGS INC.
 - LABORATORY CORP. OF AMERICA (LABCORP)
 - MERCK KGAA
 - PERKINELMER INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

QUANTERIX CORP.
QUEST DIAGNOSTICS INC.
SHIMADZU CORP.
SIEMENS HEALTHINEERS AG
SYSMEX CORP.
THERMO FISHER SCIENTIFIC INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Market Research Report | 2023-04-21 | 135 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com